General
Preferred name
CHLORPROTHIXENE
Synonyms
Minithixen hydrochloride ()
NSC 169899 ()
NSC 78193 ()
NSC 56379 ()
Minithixen ()
Truxal hydrochloride ()
Truxal ()
Clorprotixeno ()
Taractan ()
Chlorprothixene (hydrochloride) ()
Minithixen,Truxal ()
Minithixen hydrochloride, Truxal hydrochloride, NSC 169899, NSC 56379, NSC 78193 ()
CHLORPROTHIXENE HYDROCHLORIDE ()
RO 4-0403 ()
RO-4-0403 ()
N-714 ()
Ro-40403 ()
NSC-18720 ()
N-714RO 4-0403 ()
P&D ID
PD012153
CAS
113-59-7
6469-93-8
Tags
available
drug
Approved by
FDA
First approval
1967
Drug indication
Psychotic disorder
Psychosis
Drug Status
approved
withdrawn
experimental
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
INDICATION
For treatment of psychotic disorders (e.g. schizophrenia) and of acute mania occuring as part of bipolar disorders.
PHARMACODYNAMICS
Chlorprothixene is a typical antipsychotic drug of the thioxanthine class. It has a low antipsychotic potency (half to 2/3 of chlorpromazine). Chlorprothixene has not thoroughly demonstrated an antidepressant or analgesic effect but it has demonstrated antiemetic effects. It is used in the treatment of nervous, mental, and emotional conditions. Improvement in such conditions is thought to result from the effect of the medicine on nerve pathways in specific areas of the brain. Chlorprothixene has a similar side effect profile to chlorpromazine, though allergic side effects and liver damage are less frequent.
MOA
Chlorprothixene blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
TOXICITY
Symptoms of overdose include difficulty in breathing (severe), dizziness (severe), drowsiness (severe), muscle trembling, jerking, stiffness, or uncontrolled movements (severe), small pupils, unusual excitement, and unusual tiredness or weakness (severe).
METABOLISM
Hepatic
HALF-LIFE
8 to 12 hours
ABSORPTION
Incomplete bioavailability.
DESCRIPTION
Chlorprothixene can be classified as a (tricyclic) typical antipsychotic drug. The INN record stipulates the (Z) conformer. Mechanistically it acts at multiple GPCRs to mediate its neurological effects. Direct interactions with 5-HT2, dopamine D1, D2, D3, histamine H1, muscarinic and α1 adrenergic receptors have been demonstrated.
(GtoPdb)
DESCRIPTION
Chlorprothixene is a dopamine and histamine receptors antagonist with Kis of 18 nM, 2.96 nM, 4.56 nM, 9 nM and 3.75 nM for hD1, hD2, hD3, hD5 and hH1 receptors, respectively. Antipsychotic activity[1].
PRICE
29
PRICE
29
DESCRIPTION
Chlorprothixene has strong binding affinities to dopamine and histamine receptors, such as D1, D2, D3, D5, H1, 5-HT2, 5-HT6 and 5-HT7, with Ki of 18 nM, 2.96 nM, 4.56 nM, 9 nM, 3.75 nM, 9.4 nM, 3 nM and 5.6 nM, respectively.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Chlorprothixene is a typical antipsychotic drug of the thioxanthene class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.
(Enamine Bioactive Compounds)
DESCRIPTION
Chlorprothixene (Truxal) is a typical antipsychotic drug of the thioxanthene class, which was the first of the series to be synthesized.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Chlorprothixene hydrochloride is the hydrochloride salt form of chlorprothixene, a typical thioxanthine antipsychotic that functions by antagonizing dopamine D2 receptors. It can block a subset of GABAA receptors in rat cortex that is also blocked by clozapine. It exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors. It has also been shown to be effective against P. falciparum growth with an EC50 value of 1.7 µM.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Chlorprothixene hydrochloride (Truxal hydrochloride) brings strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors. Chlorprothixene hydrochloride s a typical antipsychotic drug of the thioxanthene (tricyclic) class.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
1
Compound Sets
20
AdooQ Bioactive Compound Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
ReFrame library
Selleckchem Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
39
Molecular Weight
315.08
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
0
Rotatable Bonds
3
Ring Count
3
Aromatic Ring Count
2
cLogP
5.19
TPSA
3.24
Fraction CSP3
0.22
Chiral centers
0.0
Largest ring
6.0
QED
0.65
Structural alerts
1
styrene_B(8)
c:1:c:c-2:c(:c:c:1)-[#6](-c:3:c(-[$([#16;X2]),$([#6;X4])]-2):c:c:[c;!H0,$(c-[#17]),$(c-[#6;X4])](:c:3))=[#6]-[#6]
PAINS Family C
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Immunology/Inflammation
Microbiology/virology
Neuroscience
Anti-infection
Neuronal Signaling
Indication
schizophrenia, bipolar disorder
Target
CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, HRH1, HTR2A, HTR2B, HTR2C
Bacterial
Dopamine Receptor
Histamine Receptor
5-HT
dopamine
H1 receptor
mAChR
5-HT6
5-HT7
D2
D3
MOA
Dopamine Receptor antagonist
Therapeutic Class
Antipsychotic Agents
Solubility
~10 mg/ml in PBS (pH 7.2)
~30 mg/ml in EtOH, DMSO, & DMF.
Source data
